In the early 1980s, the World Health Organization championed the Hepatitis B vaccine as a critical preventive measure. However, the prohibitive costs set by multinational pharmaceutical monopolies posed a formidable barrier, leaving the vaccine beyond the reach of most Indian families. Priced at an exorbitant USD$23 per dose, the vaccination became a luxury beyond affordability for the majority.